Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 6, 2016, Pages 1619-1626

  Inzaule, Seth C ^a,b   Weidle, Paul J ^c   Yang, Chunfu ^a   Ndiege, Kenneth ^b   Hamers, Raph L ^b   de Wit, Tobias F Rinke ^b   Thomas, Timothy ^c   Zeh, Clement ^c  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; POL PROTEIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BREAST MILK; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; PREVALENCE; TREATMENT OUTCOME; VIRUS LOAD; CHEMISTRY; CLINICAL TRIAL; ENZYMOLOGY; GENETIC SELECTION; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; ISOLATION AND PURIFICATION; MALE; MATERNAL EXPOSURE; MISSENSE MUTATION; NEWBORN; PHASE 2 CLINICAL TRIAL; PLASMA; VIROLOGY;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; MATERNAL EXPOSURE; MILK, HUMAN; MUTATION, MISSENSE; PLASMA; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; SELECTION, GENETIC;

EID: 84973333142     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw039     Document Type: Article

References (38)

1. UNAIDS. How AIDS Changed Everything. MDG6: 15 Years, 15 Lessons of Hope From the AIDS Response. 2015. http://www.unaids.org/sites/ default/files/media_asset/MDG6Report_en.pdf.
2. Both JM, van Roosmalen J. The impact of Prevention of Mother to Child Transmission (PMTCT) programmes on maternal health care in resourcepoor settings: looking beyond the PMTCT programme-a systematic review. BJOG 2010; 117: 1444-50.
3. Zeh C,Weidle PJ, Nafisa L et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8: e1000430.
4. Weidle PJ, Nesheim S. HIV drug resistance and mother-to-child transmission of HIV. Clin Perinatol 2010; 37: 825-42.
5. Saitoh A, Fenton T, Alvero C et al. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2007; 51: 4236-42.
6. Persaud D, Palumbo P, Ziemniak C et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007; 195: 1402-10.
7. Paintsil E, AndimanWA. Update on successes and challenges regarding mother-to-child transmission of HIV. Curr Opin Pediatr 2009; 21: 94-101.
8. Lidstrom J, Li Q, Hoover DR et al. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. AIDS 2010; 24: 381-6.
9. Fogel J, Li Q, Taha TE et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52: 1069-76.
10. Church JD, Omer SB, Guay LA et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving singledose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 2008; 198: 1075-82.
11. Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T et al. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV. Clin Infect Dis 2009; 49: 299-305.
12. Becquet R, Marston M, Dabis F et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS One 2012; 7: e28510.
13. Parikh UM, Koontz DL, Chu CK et al. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 2005; 49: 1139-44.
14. Hawkins CA, Chaplin B, Idoko J et al. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2009; 52: 228-34.
15. Gu Z, Gao Q, Fang H et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′- thiacytidine. Antimicrob Agents Chemother 1994; 38: 275-81.
16. Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase:genetic barriers, resistance profile and clinical implications. HIV Ther 2009; 3: 583-94.
17. Boucher S, Recordon-Pinson P, Ragnaud JM et al. HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation. HIV Med 2006; 7: 294-8.
18. Miller MD. K65R, TAMs and tenofovir AIDS Rev 2004; 6: 22-33.
19. Parikh UM, Bacheler L, Koontz D et al. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80: 4971-7.
20. Thomas TK, Masaba R, Borkowf CB et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding-the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8: e1001015.
21. Yang C, McNulty A, Diallo K et al. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol 2010; 48: 3158-64.
22. Johnson VA, Calvez V, Gunthard HF et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156-64.
23. Stanford University HIV Drug Resistance Database. Genotype-Treatment Correlations, Mutation Profiles. http://hivdb.stanford.edu/ cgi-bin/RTPosMutSummary.cgi.
24. Lole KS, Bollinger RC, Paranjape RS et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73:152-60.
25. Mirochnick M, Thomas T, Capparelli E et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53: 1170-6.
26. Coates JA, Cammack N, Jenkinson HJ et al. (2)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992; 36: 733-9.
27. Delgado E, Leon-Ponte M, Villahermosa ML et al. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study. AIDS Res Hum Retroviruses 2001; 17: 753-8.
28. Pillay V, Pillay C, Kantor R et al. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24: 1449-54.
29. Reynolds SJ, Laeyendecker O, Nakigozi G et al. Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. AIDS Res Hum Retroviruses 2012; 28: 1739-44.
30. Van Zyl GU, Liu TF, ClaassenMet al. Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. PLoS One 2013; 8:e67188.
31. van Zyl GU, van der Merwe L, Claassen M et al. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol 2011; 83: 1764-9.
32. Wallis CL, Mellors JW, Venter WD et al. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53: 480-4.
33. Coutsinos D, Invernizzi CF, Xu H et al. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009; 83: 2029-33.
34. Xu HT, Martinez-Cajas JL, Ntemgwa ML et al. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 2009; 6: 14.
35. Brodard V, Moret H, Beguinot I et al. Prevalence of detection and dynamics of selection and reversion of K65R mutation in nucleoside reverse transcriptase inhibitor-experienced patients failing an antiretroviral regimen. J Acquir Immune Defic Syndr 2005; 39: 250-3.
36. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV infection: Recommendations for a Public Health Approach. 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
37. von Wyl V, Yerly S, Boni J et al. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis 2008; 46: 1299-309.
38. UNAIDS. World AIDS Day Report. 2011. http://www.unaids.org/sites/ default/files/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf.